Furthermore, targeting LAIR1 signaling through LAIR2 overexpression32 or SHP-1 inhibition sensitizes resistant tumors to PD-1 blockade and markedly reduces tumor growth and metastasis. Here, NR0B2 is linked to neoplasm.